Skip to main content
Sinocare Inc. logo

Sinocare Inc. — Investor Relations & Filings

Ticker · 300298 ISIN · CNE100001CJ0 LEI · 3003008DEKI00A51LU77 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,252 across all filing types
Latest filing 2017-11-10 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300298

About Sinocare Inc.

https://www.sinocare.com

Sinocare Inc. specializes in the research, development, and manufacturing of biosensor technology and rapid testing products for chronic disease management. The company is primarily recognized for its blood glucose monitoring systems, including meters and test strips, which serve a global patient base. Its product portfolio extends to point-of-care testing (POCT) solutions for HbA1c, uric acid, blood lipids, and other metabolic indicators. Through the integration of advanced sensing technologies and digital health platforms, Sinocare provides comprehensive diagnostic tools for diabetes and related metabolic disorders. The company focuses on delivering affordable and accurate monitoring solutions to improve the quality of life for individuals with chronic conditions worldwide.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于《中国证监会行政许可项目审查一次反馈意见通知书》[171634]号的反馈意见回复
Capital/Financing Update Classification · 95% confidence The document is a detailed response from an independent financial advisor to the China Securities Regulatory Commission (CSRC) regarding feedback on a major asset acquisition and related fundraising by a listed company (三诺生物传感股份有限公司). It includes extensive disclosures, verifications, and opinions on various aspects of the transaction, including asset history, shareholder structure, financing, legal compliance, financial data, and valuation. The content aligns with requirements under the Chinese regulatory framework for major asset restructurings and acquisitions by listed companies. The document is not a simple announcement but a comprehensive reply with substantive financial and legal analysis related to a significant asset purchase and capital raising. This fits the category of a Capital/Financing Update (CAP) as it deals with fundraising, acquisition financing, and related disclosures. It is not an Annual Report, Interim Report, or Audit Report, nor is it a simple announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2017-11-10 Chinese
关于《中国证监会行政许可项目审查一次反馈意见通知书》[171634]号的反馈意见回复
Regulatory Filings Classification · 95% confidence The document is a detailed response to the China Securities Regulatory Commission's (CSRC) feedback on an application for issuance of shares to purchase assets and raise supporting funds. It includes extensive disclosures, financial data, legal and financial advisor opinions, and compliance with regulatory requirements related to a major asset restructuring transaction. The content covers detailed financial, legal, and operational information about the target company (PTS) and the acquiring company (SanNuo Bio-sensor Co., Ltd.), including asset valuations, financial performance, risk disclosures, and integration plans. This type of document is characteristic of a regulatory filing related to a major asset restructuring or acquisition, specifically a response to a CSRC administrative license project review feedback notice. It is not a full annual or interim report, nor an earnings release or a simple announcement. It is a comprehensive regulatory filing document addressing regulatory feedback on a major transaction filing. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2017-11-10 Chinese
发行股份购买资产并募集配套资金报告书
Capital/Financing Update Classification · 95% confidence The document is titled as a report on "发行股份购买资产并募集配套资金报告书" which translates to "Report on Issuance of Shares to Purchase Assets and Raise Supporting Funds." It contains detailed sections including transaction parties, asset evaluation, financial data, risk factors, legal compliance, and management discussion and analysis. The content is comprehensive and includes financial statements and analysis related to a major asset acquisition and capital raising. This matches the characteristics of a Capital/Financing Update (CAP) filing, which covers company fundraising, financing activities, or capital structure changes. The document is not a simple announcement or a brief summary but a full detailed report on the transaction and financing. Therefore, the appropriate classification is CAP.
2017-11-10 Chinese
关于中国证监会上市公司并购重组委员会审核公司发行股份购买资产并募集配套资金事项的停牌公告
Capital/Financing Update Classification · 95% confidence The document is a notice from a company about the suspension of trading of its stock pending review by the China Securities Regulatory Commission's Mergers and Acquisitions Committee regarding the company's issuance of shares to purchase assets and raise supporting funds. It is an announcement about a capital raising and asset acquisition process and the related trading halt, not the actual report or detailed financial data. The document is short (578 characters) and serves as an official announcement of a regulatory event related to capital/financing activities. Therefore, it fits best under Capital/Financing Update (CAP).
2017-11-10 Chinese
关于控股股东承担三诺健康或有对价支付承诺函的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by the company SanNuo Bio-sensing Co., Ltd. regarding a commitment by the controlling shareholder to bear contingent payment obligations related to a previous acquisition transaction. It discusses a share issuance to purchase equity and related financing, and a personal commitment by the controlling shareholder to cover certain payment obligations. The document is short (804 characters) and is an announcement of a shareholder commitment related to a financing/restructuring transaction rather than a full financial report or detailed filing. It does not contain financial statements or detailed financial data. It is not a report publication announcement since it contains substantive content about the shareholder's commitment. The content fits best under Capital/Financing Update (CAP) as it relates to a share issuance and financing tied to an acquisition and shareholder commitments.
2017-11-10 Chinese
中信证券股份有限公司关于《中国证监会行政许可项目审查一次反馈意见通知书》[171634]号的反馈意见回复
Capital/Financing Update Classification · 95% confidence The document is a detailed response from an independent financial advisor to the China Securities Regulatory Commission (CSRC) regarding feedback on a major asset acquisition and fundraising application by a listed company (三诺生物传感股份有限公司). It addresses numerous points related to the acquisition of assets, financial due diligence, legal and regulatory compliance, valuation, and integration plans. The content includes extensive financial, legal, and operational disclosures and opinions from financial advisors, lawyers, and accountants. The document is clearly related to a major asset restructuring and acquisition process, involving issuance of shares to purchase assets and raising supporting funds. It is not a simple announcement or a brief summary but a comprehensive reply to regulatory feedback on a significant transaction filing. This type of document aligns with filings related to major asset restructuring and capital raising activities, which fall under the category of Capital/Financing Update (CAP). It is not an Annual Report, Audit Report, or Earnings Release, nor is it a proxy or voting result announcement. The length and depth confirm it is not a mere report publication announcement or regulatory filing. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2017-11-01 Chinese

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.